<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01459965</url>
  </required_header>
  <id_info>
    <org_study_id>9307-04</org_study_id>
    <nct_id>NCT01459965</nct_id>
  </id_info>
  <brief_title>Stenting Malignant Jaundice for Quality of Life</brief_title>
  <official_title>Endoscopic Palliation of Malignant Biliary Tract Obstruction: Emphasis on Improvement in Quality of Life</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indiana University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Society for Gastrointestinal Endoscopy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>American College of Gastroenterology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Indiana University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Endoscopic stent insertion is considered the method of choice for palliation of malignant
      bile duct obstruction (MBDO). However, it can cause complications and requires periodic stent
      exchanges. While endoscopic stenting is clearly indicated for relief of cholangitis or
      refractory pruritus, its role in patients with jaundice alone is less clear. Endoscopic
      stenting for this relative indication might be justified, if there is a significant
      improvement in quality of life (QOL) of such patients. The aim of the investigators study was
      to determine whether endoscopic stenting for MBDO results in improved QOL.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Most malignant tumors causing bile duct obstruction, such as pancreatic adenocarcinoma,
      gallbladder carcinoma or cholangiocarcinoma, have an extremely poor prognosis. At the time of
      diagnosis the majority of these tumors will be unresectable with a median survival of 4-6
      months. Palliation is the goal for those patients with unresectable tumors and limited
      survival and for those at high risk for attempts at curative resection.

      Endoscopic retrograde cholangiopancreatography (ERCP) with endoscopic stent insertion is
      considered the method of choice for palliative treatment of malignant bile duct obstruction
      (MBDO). However, it can cause complications, such as pancreatitis, bleeding, perforation,
      cholangitis and stent migration in a significant proportion of treated patients. Clogging of
      plastic stents is a predictable consequence and requires periodic stent exchanges with
      attendant risks and costs. While endoscopic stenting is clearly indicated for relief of
      cholangitis or refractory pruritus, the role of stenting in patients with jaundice alone,
      abdominal pain, or failure to thrive due to malignancy is less clear. Given the risk for
      complications and costs, endoscopic therapy might be justified in these clinical scenarios if
      quality of life (QOL) is significantly improved. A few available studies have demonstrated
      improved QOL in stented patients. However, these studies include a small number of patients
      and/or are retrospective in design. Therefore, more evidence to support routine palliative
      biliary drainage in patients with MBDO is desired.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 1993</start_date>
  <completion_date type="Actual">November 2004</completion_date>
  <primary_completion_date type="Actual">November 2004</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Documented change in Quality Of Life</measure>
    <time_frame>180 days after stent insertion</time_frame>
    <description>Documented change in QOL over the first month and over six months after successful biliary drainage compared with that before the procedure. The FACT-G questionnaire administered at baseline, at 1 month after stent insertion and at 180 days after stent insertion was used to assess this outcome. Change from baseline was analyzed at each of these time points separately.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Documented change in symptoms and concerns specific for patients with MBDO</measure>
    <time_frame>180 days after stent placement</time_frame>
    <description>An additional 10 item questionnaire was administered at baseline, at 1 month after biliary stenting and at 180 days after biliary stenting.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">164</enrollment>
  <condition>Bile Duct Neoplasms Malignant</condition>
  <arm_group>
    <arm_group_label>10 French Stent</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>10 French biliary plastic stent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>11.5 French stent</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>11.5 French biliary plastic stent</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>ERCP with 10 French biliary plastic stent placement</intervention_name>
    <description>Stent placement of a 10 French biliary plastic stent</description>
    <arm_group_label>10 French Stent</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>ERCP with 11.5 French biliary plastic stent</intervention_name>
    <description>biliary plastic stent placement</description>
    <arm_group_label>11.5 French stent</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with suspected or proven malignant biliary obstruction who were unresectable
             or inoperable and were undergoing ERCP and biliary stenting for biliary depression.

        Exclusion Criteria:

          -  Had previously undergone biliary stenting

          -  Surgery was planned

          -  A guidewire could not be passed through the stricture

          -  Suspected survival of &lt; 3 months

          -  Impending duodenal obstruction
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stuart Sherman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana University School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Glen A Lehman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana Univesity Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>James Frankes, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rockford GE Associates</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John Johanson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rockford GE Associates</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tahir Qaseem, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maine Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Douglas Howell, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maine Medical Center</affiliation>
  </overall_official>
  <reference>
    <citation>Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA Cancer J Clin. 2002 Jan-Feb;52(1):23-47. Erratum in: CA Cancer J Clin 2002 Mar-Apr;52(2):119. CA Cancer J Clin 2002 May-Jun;52(3):181-2.</citation>
    <PMID>11814064</PMID>
  </reference>
  <reference>
    <citation>Lowy AM. From bad to worse: prognostic factors in pancreatic cancer. Ann Surg Oncol. 2004 Feb;11(2):117-8.</citation>
    <PMID>14761910</PMID>
  </reference>
  <reference>
    <citation>Lowenfels AB, Maisonneuve P, Boyle P (1998) Epidemiology of pancreatic cancer. In: Howard J, Idezuki Y, Ihse I, Prinz R, eds. Surgical Diseases of the Pancreas. 3rd ed. Baltimore: Williams &amp; Wilkins, 433-439</citation>
  </reference>
  <reference>
    <citation>Speer AG, Cotton PB, Russell RC, Mason RR, Hatfield AR, Leung JW, MacRae KD, Houghton J, Lennon CA. Randomised trial of endoscopic versus percutaneous stent insertion in malignant obstructive jaundice. Lancet. 1987 Jul 11;2(8550):57-62.</citation>
    <PMID>2439854</PMID>
  </reference>
  <reference>
    <citation>Andersen JR, SÃ¸rensen SM, Kruse A, Rokkjaer M, Matzen P. Randomised trial of endoscopic endoprosthesis versus operative bypass in malignant obstructive jaundice. Gut. 1989 Aug;30(8):1132-5.</citation>
    <PMID>2475392</PMID>
  </reference>
  <reference>
    <citation>Motte S, Deviere J, Dumonceau JM, Serruys E, Thys JP, Cremer M. Risk factors for septicemia following endoscopic biliary stenting. Gastroenterology. 1991 Nov;101(5):1374-81.</citation>
    <PMID>1936809</PMID>
  </reference>
  <reference>
    <citation>Tarnasky PR, Cunningham JT, Hawes RH, Hoffman BJ, Uflacker R, Vujic I, Cotton PB. Transpapillary stenting of proximal biliary strictures: does biliary sphincterotomy reduce the risk of postprocedure pancreatitis? Gastrointest Endosc. 1997 Jan;45(1):46-51. Review.</citation>
    <PMID>9013169</PMID>
  </reference>
  <reference>
    <citation>Margulies C, Siqueira ES, Silverman WB, Lin XS, Martin JA, Rabinovitz M, Slivka A. The effect of endoscopic sphincterotomy on acute and chronic complications of biliary endoprostheses. Gastrointest Endosc. 1999 Jun;49(6):716-9.</citation>
    <PMID>10343215</PMID>
  </reference>
  <reference>
    <citation>Giorgio PD, Luca LD. Comparison of treatment outcomes between biliary plastic stent placements with and without endoscopic sphincterotomy for inoperable malignant common bile duct obstruction. World J Gastroenterol. 2004 Apr 15;10(8):1212-4.</citation>
    <PMID>15069728</PMID>
  </reference>
  <reference>
    <citation>Johanson JF, Schmalz MJ, Geenen JE. Incidence and risk factors for biliary and pancreatic stent migration. Gastrointest Endosc. 1992 May-Jun;38(3):341-6.</citation>
    <PMID>1607087</PMID>
  </reference>
  <reference>
    <citation>Speer AG, Cotton PB, Rode J, Seddon AM, Neal CR, Holton J, Costerton JW. Biliary stent blockage with bacterial biofilm. A light and electron microscopy study. Ann Intern Med. 1988 Apr;108(4):546-53.</citation>
    <PMID>2450501</PMID>
  </reference>
  <reference>
    <citation>Frakes JT, Johanson JF, Stake JJ. Optimal timing for stent replacement in malignant biliary tract obstruction. Gastrointest Endosc. 1993 Mar-Apr;39(2):164-7.</citation>
    <PMID>8388345</PMID>
  </reference>
  <reference>
    <citation>Ballinger AB, McHugh M, Catnach SM, Alstead EM, Clark ML. Symptom relief and quality of life after stenting for malignant bile duct obstruction. Gut. 1994 Apr;35(4):467-70.</citation>
    <PMID>7513672</PMID>
  </reference>
  <reference>
    <citation>Pereira-Lima JC, Jakobs R, Maier M, Kohler B, Benz C, Martin WR, Riemann JF. Endoscopic stenting in obstructive jaundice due to liver metastases: does it have a benefit for the patient? Hepatogastroenterology. 1996 Jul-Aug;43(10):944-8.</citation>
    <PMID>8884318</PMID>
  </reference>
  <reference>
    <citation>Luman W, Cull A, Palmer KR. Quality of life in patients stented for malignant biliary obstructions. Eur J Gastroenterol Hepatol. 1997 May;9(5):481-4.</citation>
    <PMID>9187881</PMID>
  </reference>
  <reference>
    <citation>Abraham NS, Barkun JS, Barkun AN. Palliation of malignant biliary obstruction: a prospective trial examining impact on quality of life. Gastrointest Endosc. 2002 Dec;56(6):835-41.</citation>
    <PMID>12447294</PMID>
  </reference>
  <reference>
    <citation>Sherman S, Lehman G, Earle D, Lazaridis E, Frankes J, Johanson J, Qaseem T, Howell D (1996) Multicenter randomized trial of 10 French versus 11.5 French plastic stents for malignant bile duct obstruction. Gastrointest Endosc 43:A421</citation>
  </reference>
  <reference>
    <citation>Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, Silberman M, Yellen SB, Winicour P, Brannon J, et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol. 1993 Mar;11(3):570-9.</citation>
    <PMID>8445433</PMID>
  </reference>
  <reference>
    <citation>Cheung YB, Goh C, Thumboo J, Khoo KS, Wee J. Variability and sample size requirements of quality-of-life measures: a randomized study of three major questionnaires. J Clin Oncol. 2005 Aug 1;23(22):4936-44.</citation>
    <PMID>16051946</PMID>
  </reference>
  <reference>
    <citation>Steel JL, Eton DT, Cella D, Olek MC, Carr BI. Clinically meaningful changes in health-related quality of life in patients diagnosed with hepatobiliary carcinoma. Ann Oncol. 2006 Feb;17(2):304-12. Epub 2005 Dec 15.</citation>
    <PMID>16357021</PMID>
  </reference>
  <reference>
    <citation>Hahn EA, Cella D, (1997) Unbiased quality of life measurement across literacy levels and mode of administration. Qual Life Res 6:654.</citation>
  </reference>
  <reference>
    <citation>Yost KJ, Sorensen MV, Hahn EA, Glendenning GA, Gnanasakthy A, Cella D. Using multiple anchor- and distribution-based estimates to evaluate clinically meaningful change on the Functional Assessment of Cancer Therapy-Biologic Response Modifiers (FACT-BRM) instrument. Value Health. 2005 Mar-Apr;8(2):117-27.</citation>
    <PMID>15804320</PMID>
  </reference>
  <reference>
    <citation>Webster K, Cella D, Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System: properties, applications, and interpretation. Health Qual Life Outcomes. 2003 Dec 16;1:79. Review.</citation>
    <PMID>14678568</PMID>
  </reference>
  <reference>
    <citation>Cella D, Li JZ, Cappelleri JC, Bushmakin A, Charbonneau C, Kim ST, Chen I, Motzer RJ. Quality of life in patients with metastatic renal cell carcinoma treated with sunitinib or interferon alfa: results from a phase III randomized trial. J Clin Oncol. 2008 Aug 1;26(22):3763-9. doi: 10.1200/JCO.2007.13.5145.</citation>
    <PMID>18669464</PMID>
  </reference>
  <reference>
    <citation>Fairclough DL, Cella DF. Functional Assessment of Cancer Therapy (FACT-G): non-response to individual questions. Qual Life Res. 1996 Jun;5(3):321-9.</citation>
    <PMID>8763800</PMID>
  </reference>
  <reference>
    <citation>Jaeschke R, Singer J, Guyatt GH. Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin Trials. 1989 Dec;10(4):407-15.</citation>
    <PMID>2691207</PMID>
  </reference>
  <reference>
    <citation>Guyatt GH, Osoba D, Wu AW, Wyrwich KW, Norman GR; Clinical Significance Consensus Meeting Group. Methods to explain the clinical significance of health status measures. Mayo Clin Proc. 2002 Apr;77(4):371-83. Review.</citation>
    <PMID>11936935</PMID>
  </reference>
  <reference>
    <citation>Cella D, Hahn EA, Dineen K. Meaningful change in cancer-specific quality of life scores: differences between improvement and worsening. Qual Life Res. 2002 May;11(3):207-21.</citation>
    <PMID>12074259</PMID>
  </reference>
  <reference>
    <citation>Brucker PS, Yost K, Cashy J, Webster K, Cella D. General population and cancer patient norms for the Functional Assessment of Cancer Therapy-General (FACT-G). Eval Health Prof. 2005 Jun;28(2):192-211. Erratum in: Eval Health Prof. 2005 Sep;28(3):370.</citation>
    <PMID>15851773</PMID>
  </reference>
  <reference>
    <citation>Rege RV. Adverse effects of biliary obstruction: implications for treatment of patients with obstructive jaundice. AJR Am J Roentgenol. 1995 Feb;164(2):287-93. Review.</citation>
    <PMID>7839957</PMID>
  </reference>
  <reference>
    <citation>Kramer HJ. Impaired renal function in obstructive jaundice: roles of the thromboxane and endothelin systems. Nephron. 1997;77(1):1-12. Review. Erratum in: Nephron 1998;78(1):124.</citation>
    <PMID>9380222</PMID>
  </reference>
  <reference>
    <citation>Jiang WG, Puntis MC. Immune dysfunction in patients with obstructive jaundice, mediators and implications for treatments. HPB Surg. 1997;10(3):129-42. Review.</citation>
    <PMID>9174857</PMID>
  </reference>
  <reference>
    <citation>Cotton PB, Schmitt C. Quality of Life in palliative management of malignant obstructive jaundice. Scand J Gastroenterol Suppl. 1993;199:44-6.</citation>
    <PMID>7513440</PMID>
  </reference>
  <reference>
    <citation>Moss AC, Morris E, Leyden J, MacMathuna P. Malignant distal biliary obstruction: a systematic review and meta-analysis of endoscopic and surgical bypass results. Cancer Treat Rev. 2007 Apr;33(2):213-21. Epub 2006 Dec 8. Review.</citation>
    <PMID>17157990</PMID>
  </reference>
  <reference>
    <citation>Yeoh KG, Zimmerman MJ, Cunningham JT, Cotton PB. Comparative costs of metal versus plastic biliary stent strategies for malignant obstructive jaundice by decision analysis. Gastrointest Endosc. 1999 Apr;49(4 Pt 1):466-71.</citation>
    <PMID>10202060</PMID>
  </reference>
  <reference>
    <citation>Fitzsimmons D, Johnson CD. Quality of life after treatment of pancreatic cancer. Langenbecks Arch Surg. 1998 Apr;383(2):145-51. Review.</citation>
    <PMID>9641887</PMID>
  </reference>
  <verification_date>October 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 21, 2011</study_first_submitted>
  <study_first_submitted_qc>October 25, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 26, 2011</study_first_posted>
  <last_update_submitted>October 25, 2011</last_update_submitted>
  <last_update_submitted_qc>October 25, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 26, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Jaundice</keyword>
  <keyword>Biliary stents</keyword>
  <keyword>Palliation</keyword>
  <keyword>Quality of Life</keyword>
  <keyword>Endoscopic Retrograde Cholangiography</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Bile Duct Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

